FCGR3A and prostate adenocarcinoma: In addition, high FCGR3A expression was associated with poorer disease-free survival (DFS) in esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), LGG (Figure 4(b)), and prostate adenocarcinoma (PRAD).